bosutinib
Also known as Bosulif®, SK 606, SK-606, SKI 606, SKI-606, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Research
936 papers- Bosutinib.2012
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.Blood · 2021
- Bosutinib.2006
- Bosutinib: Pediatric First Approval.Paediatric drugs · 2024
- Bosutinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2010
via PubMed
~2 min read
Article
7 sectionsContents
- Mechanism
- Medical uses
- Contraindications
- Interactions
- Notes
- See also
- References
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.
Connections
Categories
4-Methylpiperazin-1-yl compoundsAnilinesCatechol ethersChloroarenesCyanopyridinesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs developed by PfizerDrugs with non-standard legal statusECHA InfoCard ID from WikidataNon-receptor tyrosine kinase inhibitors